Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration.

Dalal M, Jacobs-El N, Nicholson B, Tuo J, Chew E, Chan CC, Nussenblatt R, Ferris F, Meyerle C.

Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2705-9. doi: 10.1007/s00417-013-2375-7. Epub 2013 May 21.

2.

Bevacizumab for neovascular age-related macular degeneration in China.

Li X, Hu Y, Sun X, Zhang J, Zhang M; Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB)..

Ophthalmology. 2012 Oct;119(10):2087-93. doi: 10.1016/j.ophtha.2012.05.016. Epub 2012 Jul 20.

PMID:
22818896
3.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group..

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
4.

Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration.

Shah VP, Shah SA, Mrejen S, Freund KB.

Retina. 2014 Jul;34(7):1281-8. doi: 10.1097/IAE.0000000000000166.

PMID:
24695062
6.

Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.

Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M.

Ophthalmology. 2014 Jan;121(1):188-92. doi: 10.1016/j.ophtha.2013.08.035. Epub 2013 Oct 18.

PMID:
24144450
7.

Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.

Csaky KG, Dugel PU, Pierce AJ, Fries MA, Kelly DS, Danis RP, Wurzelmann JI, Xu CF, Hossain M, Trivedi T.

Ophthalmology. 2015 Mar;122(3):579-88. doi: 10.1016/j.ophtha.2014.09.036. Epub 2014 Nov 26.

PMID:
25432081
8.

Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.

Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.

Ophthalmology. 2014 Jun;121(6):1237-45. doi: 10.1016/j.ophtha.2013.12.029. Epub 2014 Mar 28.

PMID:
24684838
9.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group..

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
10.

Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.

Rush RB, Simunovic MP, Vandiver L, Aragon AV 2nd, Ysasaga JE.

Retina. 2014 May;34(5):846-52. doi: 10.1097/IAE.0000000000000033.

PMID:
24240560
11.

INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.

Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P.

Retina. 2016 Apr;36(4):770-7. doi: 10.1097/IAE.0000000000000751.

PMID:
26398691
12.

Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study.

Silva R, Cachulo ML, Fonseca P, Bernardes R, Nunes S, Vilhena N, Faria de Abreu JR.

Ophthalmologica. 2011;226(3):110-8. doi: 10.1159/000329473. Epub 2011 Aug 3.

PMID:
21822000
13.

Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.

Ophthalmology. 2016 Mar;123(3):617-24. doi: 10.1016/j.ophtha.2015.10.039. Epub 2015 Dec 11.

PMID:
26686967
14.

Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.

Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.

Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.

PMID:
22414958
15.

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups..

Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.

PMID:
23084240
16.

Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.

Kim JH, Chang YS, Kim JW, Kim CG, Yoo SJ, Cho HJ.

Ophthalmology. 2014 Apr;121(4):926-35. doi: 10.1016/j.ophtha.2013.11.004. Epub 2013 Dec 15.

PMID:
24342019
17.

Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.

Ophthalmology. 2012 Aug;119(8):1621-7. doi: 10.1016/j.ophtha.2012.02.022. Epub 2012 May 1.

PMID:
22551738
18.

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.

Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR; TREX-AMD Study Group..

Ophthalmology. 2015 Dec;122(12):2514-22. doi: 10.1016/j.ophtha.2015.08.009. Epub 2015 Sep 29.

19.

Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.

Mekjavic PJ, Kraut A, Urbancic M, Lenassi E, Hawlina M.

Acta Ophthalmol. 2011 Nov;89(7):647-53. doi: 10.1111/j.1755-3768.2009.01740.x. Epub 2009 Oct 23.

20.

Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, Sekiryu T, Okada AA, Iida T.

Am J Ophthalmol. 2015 Apr;159(4):627-33. doi: 10.1016/j.ajo.2014.12.025. Epub 2014 Dec 30.

PMID:
25555799

Supplemental Content

Support Center